CommercialCoverageMedium impact
Tumor Treating Fields Therapy
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Neurosurgery, Neurology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS MS updated their policy on Tumor Treating Fields (TTF) therapy, defining when Optune devices are medically necessary versus investigational. The policy covers TTF for newly diagnosed glioblastoma multiforme with specific criteria but considers it investigational for recurrent glioblastoma, brain metastases, mesothelioma, and lung cancer.
Action Required
Immediately: Billing team must verify TTF therapy claims meet medical necessity criteria before submission. For glioblastoma patients, confirm: age ≥18, supratentorial tumor, Karnofsky Performance Status ≥70%, and use as adjunct to temozolomide maintenance therapy following initial treatment. Flag claims for recurrent glioblastoma, mesothelioma, or lung cancer TTF therapy as investigational and likely to be denied.